Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers

Cancer Research

Volumn 70, Issue 5, 2010, Pages 1906-1915

  Creighton, Chad J ^a   Fountain, Michael D ^a   Yu, Zhifeng ^a   Nagaraja, Ankur K ^a   Zhu, Huifeng ^b   Khan, Mahjabeen ^a   Olokpa, Emuejevoke ^a   Zariff, Azam ^a   Gunaratne, Preethi H ^a,b   Matzuk, Martin M ^a   Anderson, Matthew L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; MICRORNA; MICRORNA 31; PROTEIN P53; TRANSCRIPTION FACTOR E2F2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; SENSITIVITY ANALYSIS; WILD TYPE;

BONE NEOPLASMS; CELL GROWTH PROCESSES; CYSTADENOCARCINOMA, SEROUS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICRORNAS; NEOPLASM STAGING; OSTEOSARCOMA; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950202790     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3875     Document Type: Article

References (50)

1. Cho K, Shih I. Ovarian cancer. Annu Rev Pathol 2009;4:287-313.
2. Seidman J, Horkayne-Szakaly I, Haiba M, Boice C, Kurman R, Ronnett B. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4.
3. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26:5284-93.
4. Bell D. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18Suppl 2:S19-32.
5. Bonome T, Lee J, Park D, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;65:10602-12.
6. Wu L, Belasco J. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell 2008;29:1-7.
7. Wijnhoven B, Michael M, Watson D. MicroRNAs and cancer. Br J Surg 2007;94:23-30.
8. Yu S, Chen H, Yang P, Chen J. Unique microRNA signature and clinical outcome of cancers. DNA Cell Biol 2007;26:283-92.
9. Iorio M, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-707.
10. Bearfoot J, Choong D, Gorringe K, Campbell I. Genetic analysis of cancer-implicated microRNA in ovarian cancer. Clin Cancer Res 2008;14:7246-50.
11. Nam E, Yoon H, Kim S, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-5.
12. Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008;105:7004-9.
13. Wyman S, Parkin R, Mitchell P, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009;4:e5311.
14. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990;63:132-6.
15. Creighton C, Reid J, Gunaratne P. Expression profiling of microRNAs by deep sequencing. Brief Bioinform, E-pub 2009 Mar 30.
16. Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004;20:3246-8.
17. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
18. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
19. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA. org resource: targets and expression. Nucleic Acids Res 2008;36:D149-53.
20. Creighton CJ, Nagaraja AK, Hanash SM, Matzuk MM, Gunaratne PH. A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA 2008;14:2290-6.
21. Georlette D, Ahn S, MacAlpine D, et al. Genomic profiling and expression studies reveal both positive and negative activities for the Drosophila Myb MuvB/dREAM complex in proliferating cells. Genes Dev 2007;21:2880-96.
22. Creighton C, Casa A, Lazard Z, et al. Insulin-like growth factor I (IGFI) activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26:4078-85.
23. Pollack J, Sørlie T, Perou C, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-8.
24. Nowee M, Snijders A, Rockx D, et al. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol 2007;213:46-55.
25. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009;137:1032-46.
26. Cayirlioglu P, Ward W, Silver Key S, Duronio R. Transcriptional repressor functions of Drosophila E2F1 and E2F2 cooperate to inhibit genomic DNA synthesis in ovarian follicle cells. Mol Cell Biol 2003;23:2123-34.
27. Sasaki S, Kitagawa Y, Sekido Y, et al. Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene 2003;22:3792-8.
28. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
29. Zhang Y, Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 1999;3:579-91.
30. Mason S, Loughran O, La Thangue N. p14(ARF) regulates E2F activity. Oncogene 2002;21:4220-30.
31. Cánepa E, Scassa M, Ceruti J, et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 2007;59:419-26.
32. Weinberg R. p53 and apoptosis: master guardian and executioner. In: Weinberg R, editor. The biology of cancer. New York: Garland Science, Taylor & Francis Group, LLC; 2007, p. 307-56.
33. Sherr C, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
34. Huang J, Teng L, Liu T, et al. Identification of a novel serine/threonine kinase that inhibits TNF-induced NF-κB activation and p53-induced transcription. Biochem Biophys Res Commun 2003;309:774-8.
35. Tothill R, Tinker A, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
36. Wolf J, Mills G, Bazzet L, Bast RJ, Roth J, Gershenson D. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol 1999;75:261-6.
37. Samouelian V, Maugard C, Jolicoeur M, et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFb-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol 2004;54:497-504.
38. Itamochi H, Kigawa J, Kanamori Y, et al. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther 2007;6:227-35.
39. Havrilesky L, Alvarez A, Whitaker R, Marks J, Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol 2001;83:491-500.
40. Kubo A, Nakagawa K, Varma R, et al. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res 1999;5:4279-86.
41. Mitsuuchi Y, Johnson S, Selvakumaran M, Williams S, Hamilton T, Testa J. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21/WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 2000;60:5390-4.
42. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196-9.
43. Plasencia C, Dayam R, Wang Q, et al. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormonedependent and -independent cancer cell lines. Mol Cancer Ther 2005;4:1105-13.
44. Grossel M, Baker G, Hinds P. cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain. J Biol Chem 1999;274:29960-7.
45. Lanzi C, Cassinelli G, Cuccuru G, et al. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate 2001;48:254-64.
46. Reimer D, Sadr S, Wiedemair A, et al. Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin Cancer Res 2007;13:144-51.
47. Yin H, Lowery M, Glass J. In prostate cancer C/EBPα promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT. Prostate 2009;69:1001-16.
48. Berchuck A, Kohler M, Marks J, Wiseman R, Boyd J, Bast RJ. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-52.
49. Havrilesky L, Darcy M, Hamdan H, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003;21:3814-25.
50. Kota J, Chivukula R, O'Donnell K, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.